MapLight Therapeutics (MPLT) has drawn investor attention recently as its clinical-stage central nervous system pipeline, including candidates for schizophrenia, Alzheimer’s disease psychosis and Parkinson’s disease, trades around $36.56 with a market value near $1.66 billion.

For context, MapLight Therapeutics’ share price return has been strong over 2024, with a year to date gain of 118.01% and a 90 day share price return of 19.32%. However, the 7 day share price return is down 3.46%, hinting that momentum has cooled slightly after a 9.86% 30 day share price return and a recent 1 day share price return of 3.78% at $36.56.

If you are comparing MapLight Therapeutics with other central nervous system and healthcare AI stories, this is a good moment to scan 40 healthcare AI stocks

MapLight Therapeutics looks like a focused central nervous system platform, and the stock’s sharp move over 2024 puts that story firmly in the spotlight. Does the recent rally leave the shares stretched or still reasonably priced?

Preferred Price to Book of 4.1x: Is it justified?

With MapLight Therapeutics trading at $36.56 and very limited reported revenue, the current 4.1x P/B multiple sits above both direct peers and the broader US biotech sector.

The price to book ratio compares a company’s market value to its net assets on the balance sheet and is often used when earnings are negative or volatile. For MapLight Therapeutics, this lens focuses attention on what investors are paying today relative to the company’s equity base rather than profits or sales that are not yet in place.

At 4.1x, the stock is described as expensive versus a 3.5x peer average and a 2.5x P/B level for the US biotech industry. That is a clear premium, which suggests the market is assigning extra value to MapLight Therapeutics’ central nervous system pipeline and expected revenue growth, even though forecasts indicate the business is likely to remain loss making over the next three years.

This higher multiple stands out against the sector and may prompt investors to ask whether the premium is earned by the clinical portfolio and projected top line, or whether it leaves less room for error compared with lower multiple biotech stocks. See what the numbers say about this price — find out in our valuation breakdown.

Result: Price to book of 4.1x (OVERVALUED).

However, MapLight Therapeutics still faces clear risks if clinical trial results disappoint or if ongoing losses of $199.48 million reduce investor appetite for its higher P/B premium.

Next Steps

With sentiment around MapLight Therapeutics split between concern over risk and optimism about potential rewards, this is a moment to review the numbers for yourself and act on your own judgment by weighing the 1 key reward and 4 important warning signs

Looking for more investment ideas beyond MapLight Therapeutics?

If MapLight Therapeutics has sharpened your interest in where capital might work harder, do not stop here. Broaden your watchlist with a few targeted stock ideas.

• Hunt for overlooked potential by scanning the screener containing 19 high quality undiscovered gems that pair solid fundamentals with lower market attention.
• Strengthen your core holdings by reviewing the solid balance sheet and fundamentals stocks screener (49 results) that can help support resilience through different market conditions.
• Reduce portfolio stress by checking out the 79 resilient stocks with low risk scores that screen for companies with lower risk profiles and steadier characteristics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.